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Phenotypic plasticity and epithelial-to-mesenchymal transition in the behaviour and therapeutic 
response of oral squamous cell carcinoma 
Abstract  
It is increasingly recognised that phenotypic plasticity, apparently driven by epigenetic mechanisms, 
plays a key role in tumour behaviour and markedly influences the important processes of 
therapeutic survival and metastasis. An important source of plasticity in malignancy is epithelial-to-
mesenchymal transition (EMT), a common epigenetically-controlled event that results in transition 
of malignant cells between different phenotypic states that confer motility and enhance survival. In 
this review, we discuss the importance of phenotypic plasticity and its contribution to cellular 
heterogeneity in oral squamous cell carcinoma with emphasis on aspects of drug resistance and 
EMT. 
Introduction 
Carcinomas, malignant tumours of epithelial tissues, account for the great majority of all cancers and 
cancer-related deaths. The epithelial tissues in which cancers arise include barrier tissues such as the 
intestinal epithelium, skin and oral mucosa, as well as secretory structures such as the breast and 
prostate. In oral mucosa, the predominant tumour type is squamous cell carcinoma (SCC), which 
accounts for approximately 95% of all oral tumours and, unlike SCCs of the skin, are often highly 
locally invasive (1). Oral SCCs develop from cells in the basal layer of the oral epithelium and 
originate from either altered stem cells or through dedifferentiation of early-stage differentiated 
cells (2, 3). For metastatic dissemination to occur, malignant cells need to invade through both the 
basement membrane and the underlying connective tissue (3).  Typically, oral SCC spreads by direct 
invasion or via the regional lymphatics to the cervical nodes of the neck, although haematogenous 
spread (particularly to the lungs) is possible. Metastasis to the neck, and beyond, is responsible for 
90% of all oral SCC deaths (4). Late presentation, unpredictable patterns of metastasis, and limited 
therapeutic options for more advanced disease, put oral SCC in the top ten cancers worldwide by 
mortality rate (5).  
A developmental basis for tumour heterogeneity 
The term “epigenetics” describes heritable changes that occur in genetically identical cells and drive 
the diverse patterns of cell differentiation required to build all of the tissues of a complex organism 
from a single fertilized egg. Epigenetic mechanisms that elicit transcriptional changes include gene 
promoter methylation and histone modifications (particularly changes in histone acetylation) which 
alter accessibility of the DNA to RNApol (6). Unlike permanent genetic changes, such epigenetic 
 3
changes are reversible and therefore enable a plasticity of cell phenotype. This plasticity was 
demonstrated half a century ago when it was shown by nuclear transfer experiments that the 
nucleus of a differentiated adult cell can substitute for the nucleus of a fertilized egg and drive the 
development of a new healthy adult (7). More recently, plasticity has also been demonstrated in cell 
culture, where it was found that addition of four transcription factors (Oct-4, Sox-2, c-myc and Klf4) 
was sufficient to convert a differentiated fibroblast into an embryonic stem cell that could give rise 
to all of the adult cell lineages (8). Transdifferentiation from one adult cell state to another has also 
been demonstrated, initially through cell fusion experiments using cells of two different lineages (9) 
but increasingly now through the addition of defined transcription factors (10). Although epigenetic 
states are not permanently fixed, epigenetic states imposed during development often persist in 
adult tissues to maintain the regionally-differing patterns of cell differentiation required for tissue 
renewal and function (Figure 1). This includes control of the hierarchies of stem and differentiating 
cells that underlie the continuous renewal of tissues such as the epidermis and oral mucosa (11). 
However, the potential plasticity of epigenetic states provides a mechanism for cells to adopt 
different phenotypic states and cell functions both during development and later in response to local 
signals (12). The normal diversity of epigenetic states in adult tissues has relevance for tumour 
development as tumours maintain, to a greater or lesser extent, the epigenetically-determined 
phenotypic states and patterns of differentiation seen in the parent tissue. 
Tumour heterogeneity and therapy. 
Successful treatment of oral SCC is challenging. In general, management of oral SCC is determined by 
factors that relate to the tumour (e.g. site, stage, bony invasion), the patient (physical status, 
preference) and available healthcare (expertise, cost, support). The three main treatment modalities 
for both curative and palliative management are surgery, radiotherapy and chemotherapy, which 
can be used in isolation or in combination with one another. Ionising radiation and 
chemotherapeutic agents, (usually platinum-based cisplatin, or combinations with 5-FU or newer 
taxanes) lead to DNA damage in dividing cancer cells, inducing cell death through apoptosis (13).  
Given its high success rate, primary radiotherapy may be the only treatment modality needed for 
small tumours, particularly those found in the soft palate, base of tongue and tonsillar region.   
However, despite optimal surgical resection or primary radiotherapy, local recurrences and 
metastatic spread still occur. Indeed, incidences of systemic spread are increasing (14). Current 
standard radiation and surgical regimes may fail to eradicate all cancer cells as a few such cells may 
have invaded far beyond planned surgical and/or radiotherapy fields, and spread via the lymphatics 
or vasculature. There is a high likelihood that these disseminated cells might drive the growth of a 
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recurrent tumour, either at, or near, the primary site or at a distant secondary site (15). There is also 
evidence to suggest that such recurrent tumours are more aggressive compared to the initial, 
primary tumour, and that they display greater resistance to chemotherapeutic agents (16).  
Resistance to chemotherapeutic agents can lead to treatment failure. Mutational changes occurring 
within a tumour can lead to increasing acquisition of therapeutic resistance by a process of clonal 
evolution (17). When subjected to a therapeutic challenge, cells within a tumour can undergo a form 
of Darwinian selection allowing genetic variants better able to withstand therapy to grow to become 
dominant populations. Epigenetic mechanisms can similarly provide cancer cells with differing 
resistances to therapeutic challenge (18). Unlike genetic changes, however, epigenetic changes can 
be driven by cellular signalling mechanisms derived from the tumour microenvironment through 
factors such as inflammation or hypoxia (19, 20).  This provides a mechanism by which factors 
extrinsic to a tumour can influence its therapeutic responses. The flexibility of epigenetic changes 
means that, following a therapeutic insult, a small population of epigenetically-resistant cells can 
recapitulate a diversity of cell populations similar to those that comprised the original tumour. Such 
epigenetic changes can co-operate with genetic mechanisms to give a tumour time to acquire 
further resistance through mutation (21). 
Aside from therapeutic resistance, another major question in cancer biology is that of invasion and 
metastasis. Malignant neoplasms range from well differentiated to undifferentiated, differentiation 
referring to the extent to which parenchymal cells resemble normal cells. Well-differentiated 
malignancies are less aggressive in nature, and less likely to metastasise, instead forming more 
discrete growths. Although they recognise no normal anatomic boundaries, their growth is more 
predictable and they are more amenable to surgical resection. Such tumours may have a good 
prognosis but many tumours, particularly those that are poorly- or un-differentiated, are much more 
likely to invade early into the surrounding tissue and metastasise via the lymphatic and circulatory 
systems. Complete surgical resection, where appropriate, is rendered more difficult, and prognosis is 
generally poorer compared to the well-differentiated malignancy. As is the case with therapeutic 
resistance, the ability to generate different epigenetic states is thought to be a key attribute of those 
tumours that can invade and metastasise (18). Employing this method, proliferating tumour cells can 
switch to a migratory phenotype allowing them to escape from the primary tumour and migrate to a 
distant site before then switching back to the initial proliferative phenotype to drive secondary 
tumour growth (15).  
Two factors that must be delineated from each other are inter-tumoral and intra-tumoral genetic 
and epigenetic heterogeneity. Inter-tumoral heterogeneity is an important determinant of whether 
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a tumour has the ability to metastasise or resist therapy, and may underlie the large variation in 
progression and therapeutic response seen between different tumours. Intra-tumoral 
heterogeneity, by giving rise to a diversity of tumour cells with differing attributes within a single 
tumour, enables tumours to perform processes that confer therapeutic resistance and the ability to 
metastasise. Factors such as the initial genetic insults (a genetic difference) and the developmental 
state of the tumour cell of origin (an epigenetic difference) are likely to be of crucial importance to 
both types of heterogeneity. These two types of heterogeneity can be considered linked insofar as 
they both control what types of cells a particular tumour is capable of producing, and whether it 
contains cell types that are able to resist therapeutic interventions or invade and metastasise (Figure 
2). It seems probable that both genetic and epigenetic factors cooperate to drive the processes that 
are observed in tumour development and progression.  
Epithelial-to-mesenchymal transition, an important developmental process that drives tumour 
heterogeneity in oral squamous cell carcinoma.  
One important epigenetic transition that provides a mechanism for both therapeutic survival and 
invasion/metastasis is epithelial-to-mesenchymal transition (EMT).  During EMT, cells lose epithelial 
characteristics and gain mesenchymal ones, thereby enhancing their ability to migrate. This is 
achieved following a number of steps that lead to epithelial cells losing both their cell adhesiveness 
and apical-basal polarity, and undergoing both cytoskeletal and signalling changes which confer 
invasive properties. 
EMT was first described as a process occurring during early embryonic development whereby 
ectodermal cells are enabled to migrate to the centre of the embryo to give rise to mesoderm (22). 
EMT also occurs later in development, initially for the specification of neural crest cells at the border 
between the developing neural tube and the rest of the ectoderm, and then to create specialist 
mesenchyme in various organs (23). During development, the reverse process of mesenchymal-to-
epithelial transition (MET) also occurs, where populations of cells that have undergone EMT earlier 
in development return to an epithelial phenotype to give rise to secondary epithelial tissues such as 
the endocardium, epicardium, and urogenital precursors (23). These developmental processes point 
to a striking plasticity between epithelial and mesenchymal identities. 
As well as at the earliest stages of life, EMT also occurs in inflammation in normal adult tissues. For 
example, during wound healing, epithelial cells at the wound edge undergo EMT which allows them 
to migrate directly into the wound. This normally follows exposure to a variety of stromal EMT-
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inducing signalling factors from which they were previously isolated (24, 25). Tissue inflammation 
also aids EMT by facilitating recruitment of EMT-inducing immune cells to the wound site (26).  
The process by which cells undergo a change from the epithelial phenotype to the mesenchymal is 
mediated by several stromal signals, including TGFβ, Il6 and TNFα, with TGFβ currently the most 
studied. After TGFβ binds to its cell receptors, the resulting nuclear translocation of Smad family 
transcription factors leads to interaction with transcription factors from the Snail, Twist and Zeb 
families, the EMT ‘master regulators’ (27-31). Other pathways downstream of TGFβ that support 
EMT include phosphatidylinoitol-3-kinase (PI3K) and mitogen-associated protein kinase (MAPK) (32). 
Together, their activity acts to repress those genes responsible for cell adhesion and polarity, such as 
RhoA and E-cadherin. This is supported by the loss of epithelial-specific intermediate filament 
keratin, and repression of claudin and occludin expression, all of which normally contribute to cell 
junctions. This repression is maintained through EMT (33). Additionally, N-cadherin is upregulated 
during EMT as E-cadherin is downregulated, the ‘cadherin switch’ (34). TGFβ also mediates other 
properties of EMT cells, such as anti-apoptosis whereas in non-EMT cells it can have a pro-apoptotic 
role (35, 36). Other pathways involved in EMT involve hypoxia-inducible factor (HIF), which not only 
induces Twist and Snail expression, but also positively impacts upon pro-EMT β-catenin. β-catenin is 
normally kept at the plasma membrane of epithelial cells by E-cadherin (12) but HIF activity acts to 
support its translocation to the nucleus where it increases EMT-associated gene activity (37, 38). The 
Wnt signalling pathway plays a similar role in supporting the nuclear translocation of β-catenin (via 
inhibition of glycogen synthase kinase 3β) and thus acts to support and maintain EMT (39). Receptor 
tyrosine kinase activation, by the binding of growth factors to the receptor tyrosine kinases, also 
induces EMT via up-regulation of Snail expression (40). Recent work has begun to explore the role of 
non-coding microRNAs, that selectively bind mRNAs and inhibit their translation, in modulating EMT. 
For example, the EMT-inhibitory miR-200 family of microRNAs represses translation of Zeb1 and 
Zeb2 mRNAs (41) and Zeb1 acts to suppress the miR-200 family (42). These mechanisms all support 
the loss of cell-cell attachments and the acquisition of a migratory mesenchymal phenotype.  
As well as its physiological roles, EMT has now been shown to have several important roles in cancer 
(12), where EMT is promoted by both the inflammatory immune response (26, 43) and the hypoxic 
tumour environment (19, 44). A central role for EMT in the metastasis of several types of carcinoma, 
including oral SCC (44) and breast cancer (45), has been described. In some malignancies, cells 
appear to be primed to undergo EMT, possibly due to the possession of a range of relevant 
mutations (e.g. in receptor tyrosine kinase or Wnt signalling pathways) that predispose cells to 
undergo EMT (46).  
 7
Once cellular adhesion has been lost the resulting mesenchymal-like cells secrete matrix 
metalloproteinases (MMPs), allowing them to breach the basement membrane and invade into the 
tissue beyond (32). This is supported by cytoskeletal reorganization of the cell, itself enhanced by a 
key EMT protein, Vimentin, which allows the cell to develop cellular protrusions known as filopodia, 
lamellipodia and invadipodia (47, 48). These protrusions act to ‘sense’ the environment, support 
motility and secrete MMPs, leading to the behavior that typifies the EMT cell phenotype. The MMPs 
also act in a manner to support and maintain EMT in themselves, in a positive feedback mechanism 
(49). 
A mouse xenograft study of oral SCC has shown that the hypoxia-inducible factor HIF1α 
transcriptionally upregulates the EMT-inducing transcription factor Twist. This promotes EMT and 
metastasis of oral SCC, and expression of HIF1α or Twist in primary human tumours can be 
correlated with metastasis and poor prognosis (44, 50). Other studies have demonstrated a 
correlation of upregulated Vimentin and downregulated E-cadherin with tumour invasion and 
metastasis (51-53). EMT not only facilitates movement but has also been implicated in therapeutic 
survival (54-56). Studies of both oral SCC and breast cancer have reported that EMT endows cancer 
cells with heightened resistance to chemotherapeutic agents and radiotherapy (54-56). Oral SCC 
cells that have undergone EMT have reduced oxygen consumption and greatly reduced production 
of reactive oxygen species (ROS), combined with upregulation of the ROS scavenger SOD2 (19). As 
reduced ROS and upregulated ROS scavengers have been shown to be associated with cancer 
radioresistance (16), this may form an important mechanism underlying the therapeutic resistance 
of cells that have undergone EMT.  
The mechanisms inducing EMT have been extensively studied but, beyond the withdrawal of EMT 
inducing signals, there is little information about what induces the reverse process of MET. However, 
it is apparent that oral SCC cells are capable of entering two different states of EMT; one that is fixed 
and precludes return to an epithelial state, and another that is plastic and can undergo spontaneous 
MET to return to an epithelial phenotype (57, 58). As postulated by Brabletz (15), the combination of 
EMT and MET provides a mechanism for metastasis, as tumour cells can migrate away from the 
primary tumour and then undergo MET to enable new tumour growth (covered in detail in (59)). 
This concept is supported by findings that EMT can be detected at the invasive tumour edge and that 
secondary tumours typically re-express the same epithelial characteristics as the corresponding 
primary tumour (15). Direct evidence has now been provided by several recent studies (reviewed, 
(60)). One particularly interesting study (61) used a mouse model of metastatic skin SCC, in which 
tumours were induced by topical application of the chemical carcinogens DBMA and TPA. The mice 
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carried a doxycycline-inducible Twist-1 transgene, under the control of the Keratin 5 promoter, and 
this allowed selective induction of Twist expression leading to EMT in keratinocytes exposed to 
doxycycline. Systemic delivery of doxycycline induced Twist in all cancer cells, whereas local topical 
application of doxycycline was used to induce Twist only in the cells in the primary tumour. Systemic 
and topical doxycycline both increased the number of tumour cells entering the circulation and 
extravasating to the lung but only topical doxycyclin resulted in an increased number of metastases, 
a difference interpreted as a requirement for reversal of EMT-associated growth arrest at the 
metastatic site and as evidence for sequential EMT and MET as drivers of metastasis in SCC (61). 
Not all epigenetic mechanisms are of equivalent stability. In the case of fully repressed 
heterochromatin, genes are turned off in an essentially permanent fashion (with the exception of 
the special case of nuclear reprogramming to pluripotency, although even here there is great 
resistance to the reversal of heterochromatic states (62)). However, there is an epigenetic state 
termed “bivalent chromatin” that silences genes in such a way that the chromatin (DNA-histone 
complex) is still relatively open and genes are thus poised to be expressed when the correct 
combination of transcription factors is present. Bivalent chromatin was first discovered in embryonic 
stem cells where it enables many genes to remain poised to induce differentiation into a variety of 
lineages (63), but it is now known that key genes involved in EMT exist in a bivalent chromatin state 
in cancer cells; this facilitates phenotypic plasticity and enables cells to undergo EMT in response to 
various signalling cues (64). Further, it has been shown in breast cancer that cells that undergo EMT 
in response to stromal signals possess bivalent chromatin at the Zeb1 promoter, whereas those cells 
in which stromal signals cannot induce EMT possess a heterochromatic Zeb1 promoter (65). This 
provides a possible epigenetic mechanism for both inter-tumoral and intra-tumoral differences in 
the ability to undergo EMT. 
Given the relative resistance to standard therapies of cells that have undergone EMT, it is now 
increasingly recognised that new ways of targeting these cells must be found. In malignant disease, 
the obvious aim is to impede or stop cells undergoing invasion and metastasis and the role of a 
number of drugs is currently being investigated. For example, after using E-cadherin shRNA to 
induce an EMT phenotype in breast cancer cells, the antibiotic Salinomycin was identified as an 
agent that could specifically target EMT cells (56). However, the mechanism by which it acts is yet to 
be elucidated. Another drug, Metformin, the oral anti-diabetic, has also been shown to target EMT 
cells in breast cancer (66) by inhibiting nuclear translocation of the EMT-inducing inflammatory 
transcription factor NF-κB (67). The polyphenol Revesterol has been shown to downregulate the key 
EMT master regulators Snail1, Snail2 and Zeb1 in mouse models of pancreatic cancer by repressing 
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their transcription (68). As pathways behind EMT are better understood, newer agents will be added 
to those currently being investigated.  
Targeting signalling molecules that are important for maintenance of the EMT phenotype also 
provides a promising approach. One possible target is the cell surface glycoprotein CD44, which is 
involved in a variety of signalling pathways in cancer (69, 70) and is highly expressed on oral SCC cells 
that have undergone EMT (57). Due to alternative splicing of 9 variant exons, CD44 exists in many 
different isoforms that have different effects on cellular properties (70, 71). It has recently been 
demonstrated, for both oral SCC and breast cancer, that it is the standard isoform of CD44 
containing no variant exons that is highly expressed on cells that have undergone EMT (71, 72). This 
might provide an opportunity for the development of anti-CD44 therapies that selectively target 
EMT cells.  
Oral SCC is a potentially devastating disease, management of which often entails radical surgical 
intervention and extremely taxing chemo-radiotherapy regimes. Although survival and disease-free 
outcomes appear to have improved in recent years (73), the potential for significant further 
improvement exists. An extensive body of research now points to the key role of EMT in metastasis, 
in oral SCC and other cancers, and a better understanding of the complexities behind this process 
may offer the opportunity to modify, or develop new, chemotherapeutic agents which may serve to 
improve outcomes. Undoubtedly, new methods must be found that target EMT cells, or at least 
include them in therapeutic regimes, and a considerable amount of research effort is now being 
directed at this pressing issue. 
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Figure legends 
Figure 1 – A limited level of epigenetic plasticity. This figure shows the ‘Epigenetic Landscape’ 
(Conrad Waddington, 1957) that has become the classic depiction of lineage restriction during 
development. The ball at the top of the hill represents a cell possessed of the totipotent state 
present in the fertilized egg (or the pluripotent state present in embryonic stem cells). As it rolls 
down the hill (representing fate choices during development) the cell must make choices between 
various valleys that restrict its future choice of identity. Epigenetic mechanisms close off genetic 
networks governing alternative lineages, leading to a restricted choice of cellular identity. However, 
it has recently become apparent that some cell types that were thought to be lineage-restricted (at 
the bottom of the hill) still possess a certain level of epigenetic plasticity, and one example of this is 
the ability to switch between epithelial and mesenchymal lineages by undergoing epithelial-to-
mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET). The poised state of 
‘bivalent chromatin’ may be an important epigenetic state that enables this plasticity. 
Figure 2 - Scheme illustrating the causes of inter-tumoral and intra-tumoral heterogeneity, and the 
consequences for therapy. In this scheme, two different epithelial cells of origin possess different 
epigenetic states and thus give rise to inter-tumoral heterogeneity. Cell of origin 1 (light blue) 
possesses a greater potential for phenotypic plasticity than cell of origin 2 (green), and thus requires 
fewer mutational events in order to facilitate epithelial-to-mesenchymal transition (EMT) (red cells). 
Differing mutational events in the cell of origin produce tumours with different genetic states, also 
contributing to inter-tumoral heterogeneity. Intra-tumoral heterogeneity in developing tumours can 
be driven by a) epigenetic changes (EMT, or differentiation into an alternative epithelial state), or b) 
mutational events in individual tumour cells to create genetically distinct clones within the tumour. 
Such events, creating intra-tumoral heterogeneity, also contribute to inter-tumoral heterogeneity 
and the breadth of differences in behaviour and therapeutic response between tumours. Intra-
tumoral heterogeneity may enable a subset of tumour cells to survive a single type of therapy, 
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suggesting that it will likely be necessary to develop combinatorial therapies to ensure that all 
tumour cells are targeted. 
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